Aclaris Therapeutics (ACRS) Total Liabilities (2017 - 2025)
Historic Total Liabilities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $55.4 million.
- Aclaris Therapeutics' Total Liabilities rose 610.8% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.4 million, marking a year-over-year increase of 610.8%. This contributed to the annual value of $64.8 million for FY2024, which is 6102.27% up from last year.
- Latest data reveals that Aclaris Therapeutics reported Total Liabilities of $55.4 million as of Q3 2025, which was up 610.8% from $57.4 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Total Liabilities ranged from a high of $64.8 million in Q4 2024 and a low of $27.2 million during Q2 2024
- Its 5-year average for Total Liabilities is $50.1 million, with a median of $52.9 million in 2023.
- Per our database at Business Quant, Aclaris Therapeutics' Total Liabilities plummeted by 5125.32% in 2024 and then surged by 11067.93% in 2025.
- Aclaris Therapeutics' Total Liabilities (Quarter) stood at $53.9 million in 2021, then rose by 5.76% to $57.0 million in 2022, then decreased by 29.4% to $40.2 million in 2023, then soared by 61.02% to $64.8 million in 2024, then dropped by 14.42% to $55.4 million in 2025.
- Its Total Liabilities was $55.4 million in Q3 2025, compared to $57.4 million in Q2 2025 and $54.0 million in Q1 2025.